

**Title: Efficacy and safety of 10-day versus 14-day bismuth-containing quadruple therapy for *H. pylori* eradication: A systematic review and meta-analysis**

Najam Gohar MBBS <sup>a</sup>, Zoya Ejaz MBBS <sup>b</sup>, Faizan Ahmed MBBS <sup>a</sup>, Abdul Rafay MBBS <sup>c</sup>, Abdullah Humayun MBBS <sup>d</sup>, Momna Nisar MBBS <sup>e</sup>, Ali Mushtaq MBBS <sup>f</sup>, Aanusha Ghouri MBBS <sup>e</sup>, Fatima Zafar MBBS <sup>g</sup>, Hira Khalid MBBS <sup>h</sup>, Sania Afzal MBBS <sup>i</sup>, Hammad Khan MBBS <sup>j</sup>, Huzaifa Ahmed Cheema MBBS <sup>j</sup>, Muhammad Shahzil MD <sup>k</sup>, Essam Rashad MD <sup>l</sup>, Rehmat Ullah Awan MD <sup>m</sup>, Prasun K Jalal MD <sup>n</sup>

- a. Department of Medicine, Ameer-ud-Din Medical College, Lahore, Pakistan
- b. Department of Medicine, Jinnah Hospital, Lahore, Pakistan
- c. Department of Medicine, Lahore Medical and Dental College, Lahore, Pakistan
- d. Department of Medicine, Rawalpindi Medical University, Rawalpindi, Pakistan
- e. Department of Medicine, Allama Iqbal Medical College, Lahore, Pakistan
- f. Department of Medicine, The Aga Khan University, Karachi, Pakistan
- g. Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan
- h. Department of Medicine, Shifa College of Medicine, Shifa Tameer-e-Millat University, Islamabad, Pakistan
- i. Department of Medicine, Faisalabad Medical University, Faisalabad, Pakistan
- j. Department of Medicine, King Edward Medical University, Lahore, Pakistan
- k. Department of Internal Medicine, Milton S Hershey Medical Center, The Pennsylvania State University, Hershey, PA, USA
- l. Department of Internal Medicine, Parkview Regional Medical Center, Fort Wayne, IN, USA

- m. Department of Gastroenterology and Hepatology, West Virginia University, Morgantown, WV, USA
- n. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA

### **Corresponding Author**

- 1. Muhammad Hammad Khan, MBBS

[hammad.k.999@gmail.com](mailto:hammad.k.999@gmail.com)

- 2. Huzaifa Ahmed Cheema, MBBS

[huzaifaahmadcheema@gmail.com](mailto:huzaifaahmadcheema@gmail.com)

Department of Medicine, King Edward Medical University, Lahore, Pakistan

Neela Gumbad, Mayo Hospital Road, Lahore, Pakistan

+923334798001

### **Credit Author Statement**

**Najam Gohar:** Conceptualization, Methodology, Formal Analysis, Software, Data curation, Writing, Original draft preparation; **Zoya Ejaz:** Data curation, Methodology, Investigation, Writing - original draft; **Faizan Ahmed:** Data Curation, Methodology, Investigation, Validation, Visualization, Writing - original draft; **Abdul Rafay:** Data Curation, Writing - original draft,

Visualization; **Abdullah Humayun:** Data Curation, Writing – Original draft; **Momna Nisar:** Data Curation, Writing – Original draft; **Ali Mushtaq:** Visualization, Validation, Writing-Original draft; **Aanusha Ghouri:** Writing - original draft, Investigation, Visualization; **Fatima Zafar:** Writing - original draft, Investigation, Validation; **Hira Khalid:** Investigation, Visualization, Validation; **Sania Afzal:** Investigation, Visualization; **Hammad Khan** Supervision, Writing – original draft, review & editing; **Huzaifa Ahmed Cheema** Supervision, Writing – review & editing; **Muhammad Shahzil:** Writing – review & editing; **Essam Rashad:** Supervision, Writing – review & editing; **Rehmat Ullah Awan:** Supervision, Writing – review & editing; **Prasun K Jalal:** Supervision, Writing – review & editing.

### **Declaration of Interest**

The authors have no conflict of interest

### **Funding**

The authors received no funding.

### **Disclosure Statement**

The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.

## Highlights

- Our meta-analysis comprising 2424 patients showed that patients receiving 10-day bismuth-containing quadruple therapy had comparable eradication rates to those receiving 14-day bismuth-containing quadruple therapy for *Helicobacter pylori*.
- Additionally, there was no significant difference between the two groups for compliance and risk of adverse events.
- Antibiotic resistance was associated with lower eradication rates in both treatment groups.

## Keywords

*Helicobacter pylori*; Bismuth-containing quadruple therapy; eradication; Meta-analysis.

## Abbreviations

**BQT** = Bismuth-containing quadruple therapy

**ITT** = Intention-to-treat

**PP** = Per protocol

**UBT** = Urea breath test

## **Abstract**

### **Background**

Nearly half of the world population is infected by *Helicobacter pylori* (*H. pylori*). Bismuth-containing quadruple therapy (BQT) has shown favorable outcomes. This study compares 10-day and 14-day BQT regimens to evaluate their efficacy, safety, and compliance rates.

### **Methods**

We searched electronic databases from their inception until May 2024 to retrieve all randomized controlled trials (RCTs) that compared 10-day and 14-day BQT regimens for *H. pylori* eradication. Meta-analysis was performed using Review Manager 5.4. Dichotomous outcomes were compared using risk ratio (RR).

### **Results**

Seven RCTs and a total of 2,424 patients were included in the meta-analysis. There was no significant difference in the intention-to-treat eradication rate (RR 0.97; 95% CI 0.94, 1.01) and the per-protocol eradication rate (RR 0.96; 95% CI 0.93, 1.00) between the 10-day BQT and 14-day BQT groups. Commonly reported adverse events in both groups were epigastric pain and discomfort, nausea, and vomiting. There was no significant difference in the risk of adverse events between the two groups (RR 0.80; 95% CI 0.63, 1.02). There was no significant difference in the compliance rate between the two groups (RR 1.02; 95% CI 1.00, 1.04).

### **Conclusion**

The eradication rates, risk of adverse events, and compliance rates were comparable between the two groups. Future research comparing similar drug doses with larger sample sizes and longer patient follow-ups can improve the quality of results.

## Introduction

A significant proportion of the world's population is afflicted by *Helicobacter pylori* (*H. pylori*) infection. In 2015, around 4.4 billion people worldwide were reportedly impacted by this infection [1]. The burden of *H. pylori* infection is higher in developing countries than in developed countries, with the highest prevalence in African and Eastern Mediterranean regions. The adult population is affected by *H. pylori* infection more than children and adolescents, with a prevalence rate of 43.9% and 35.1% respectively [2]. *H. pylori* is recognized as the causative agent of various gastrointestinal conditions, including chronic gastritis, peptic ulcers, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma [3,4].

Untreated *H. pylori* infection can result in accelerated loss of specialized glands in the stomach, leading to atrophic gastritis and increasing the risk of gastric carcinoma. Seeking timely effective treatment is crucial in preventing detrimental outcomes [5]. Elimination of infection is cost-effective, especially for high-risk individuals. The treatment costs in patients with successful eradication were found to be almost half that accrued by the individuals with treatment failure and associated complications [6].

Triple or quadruple therapy are the two commonly employed regimens for eradicating infection. Triple therapy includes a combination of a proton pump inhibitor (PPI) and two antibiotics, such as amoxicillin and clarithromycin or metronidazole. The efficacy of triple therapy is declining due to antibiotic resistance [7]. Quadruple therapy, which consists of adding bismuth to the triple therapy, is effective in areas with high antibiotic resistance [8]. In a meta-analysis, it was found that quadruple therapy has better cure rates than triple therapy [9].

The duration of bismuth quadruple therapy is still under evaluation. The previous systematic review and meta-analysis comparing the two treatment regimens exhibited comparable eradication rates, with a lower risk of adverse events in the 10-day bismuth-containing quadruple therapy (BQT) group. However, since the previous meta-analysis, three RCTs [10–12] have been published that have conflicting outcomes to one another and have not been incorporated into a meta-analysis, with one being the largest trial comparing the two regimens to date [10]. The new studies collectively comprise a sample size greater than the previous meta-analysis. A shorter duration of therapy can improve patient compliance, with potential savings in healthcare expenses and fewer drug shortage concerns.

This meta-analysis aimed to assess the effectiveness of 10-day BQT compared to 14-day BQT and to profile the adverse events associated with both treatment durations.

## **Materials and Methods**

This systematic review was conducted according to the methodological guidelines outlined in the Cochrane Handbook for Systematic Reviews of Interventions. The reporting follows the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement [13]. The review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) under the identifier CRD42024551033. Ethical approval was not required for this study.

## **Eligibility Criteria**

The inclusion criteria were as follows: 1) study design: RCTs; 2) population: adults over 18 years of age, undergoing medical therapy for *H. pylori* eradication; 3) intervention: 10-day BQT

therapy (quadruple therapy was defined as a combination of three medications including a PPI, and two antibiotics with any formulation of bismuth); 4) comparator: 14-day BQT therapy; 5) outcomes: reporting any outcome of interest.

The exclusion criteria were: 1) study designs other than RCTs, such as case series and case reports, quasi-randomized trials, and observational studies; 2) treatment regimens other than 10 and 14 days BQT; 3) treatment regimen not having bismuth in it; 4) studies conducted on animals; and 5) studies in languages other than English.

## **Information Sources**

A comprehensive search strategy was employed to identify relevant studies. We searched electronic databases and international trial registries from inception to May 2024. The search was conducted using the Cochrane Central Register of Controlled Trials (via The Cochrane Library), MEDLINE (via PubMed), Embase (via Ovid), ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (ICTRP) portal. No language restrictions were applied. Additionally, grey literature sources such as ProQuest Dissertations & Theses Global and OpenGrey were explored for potentially relevant data. Reference lists of included articles and relevant systematic reviews were hand-searched to identify further eligible studies. Forward citation tracking was conducted using the Web of Science to retrieve any additional pertinent research. A detailed search strategy utilizing keywords and Medical Subject Headings (MeSH) terms related to 10 and 14-day bismuth-containing quadruple therapy, *Helicobacter pylori*, and eradication is provided in **Supplementary Table 1**.



## **Selection Process**

A two-stage screening process was employed for article selection. All retrieved citations were uploaded to Rayyan AI, a web-based platform for systematic reviews. Two authors independently screened titles and abstracts against pre-defined eligibility criteria. Next, full-text articles of potentially eligible studies were retrieved and independently reviewed by the same authors. Disagreements were resolved through arbitration by a senior author.

## **Data Collection Process and Data Items**

After the process of study selection, data were extracted by two reviewers into a pre-piloted Microsoft Excel spreadsheet to ensure consistency of data extraction. Relevant data items were extracted, including patient characteristics (number of participants, their mean age in years, percentage of male population, confirmatory diagnosis for *H. pylori* infection, treatment-naïve population), intervention details (including study arms and regimen), comparator details (14-day BQT regimen), study characteristics (trial name, first author, year of publication, name of country in which the study was conducted, duration of follow-up), and the outcome variables. Our primary outcomes were the intention-to-treat eradication rate and the per-protocol eradication rate. The intention-to-treat analysis (ITT) includes all participants who were randomized at the beginning of the study, irrespective of whether they completed the prescribed treatment or follow-up. Per-protocol (PP) only considers those participants in the analysis who completed the therapy as described in the protocol, without any major violations. Secondary outcomes included the incidence of adverse events and the compliance rate.

## **Risk of Bias Assessment**

Two authors assessed the risk of bias in the included studies using the revised Cochrane Risk of Bias tool for randomized trials (RoB 2.0) [14], which assesses bias in the following 5 domains: 1) bias arising from the randomization process; 2) bias caused by deviations from intended interventions; 3) bias caused by missing outcome data; 4) bias in the measurement of the outcome, and 5) bias in the selection of the reported result. Two authors independently rated the risk of bias for each included study as low, high, or some concerns. A third author resolved any disagreement between them.

### **Data Synthesis**

We used Review Manager (RevMan, version 5.4; The Cochrane Collaboration, Copenhagen, Denmark) for statistical analysis. Dichotomous outcomes were reported as relative risk (RR) with 95% confidence intervals (CIs). The random-effects model with the Mantel-Haenszel method was used to perform meta-analyses. A two-tailed *p*-value less than 0.05 was taken to be significant.

For each synthesis, the  $I^2$  index and the chi-square test were used for the assessment of heterogeneity, and a *p*-value of <0.1 was considered significant for the heterogeneity of the included studies.

### **Results**

The study selection process is illustrated in the PRISMA flowchart in **Figure 1**. An initial search yielded 309 studies. After removing duplicates, screening titles, and abstracts, the studies were assessed by their full-text manuscripts. Subsequently, seven RCTs were included in the analyses.

**Table 1** summarizes the main characteristics of all included studies, such as age, country, and treatment drugs. Seven RCTs [10–12,15–18] of BQT were analyzed to compare the eradication rates of treatment durations of 10 and 14 days. All studies reported both ITT and PP eradication rates for the specified treatment durations. Additionally, one of the studies [16] had two pairs of intervention and control groups (10-day and 14-day bismuth-quadruple therapies and moxifloxacin-bismuth combined therapies), which were pooled separately in the meta-analysis. The studies also reported overall incidence of adverse effects and patient compliance. In the trials, 2424 patients were assigned to either the 10-day duration group (n = 1223) or the 14-day duration group (n = 1201). The trials were conducted in China (4 trials), Italy, Turkey, and Taiwan. All trials enrolled treatment naïve patients. Confirmation of *H. pylori* diagnosis was made by 13-C Urea breath test (13C-UBT), gastric biopsy and histology, and tissue culture. Detailed study characteristics are provided in the **supplementary table S2**.

### **Risk of Bias Assessment**

One study exhibited a low risk of bias, while there were some concerns of bias in the other six studies. These concerns mainly arose due to issues in the randomization process (two studies) and the selection of reported results (four studies). Additionally, one study had a considerable loss of population to follow up. The details of the bias assessment are provided in the **supplementary table S3**.

### **Results of the meta-analysis**

#### *Eradication Rate*

Seven studies reported data on the eradication rate. For the ITT analysis, the eradication rate for the 10-day group was 86.6%, while that for the 14-day group was 90.3%. There was no significant difference between the two treatment groups (RR 0.97; 95% CI 0.94, 1.01;  $I^2=38\%$ ) (**Figure 2**). In the PP analysis, the eradication rates were 90.8% and 96.0% in the 10-day and the 14-day groups, respectively, there was no statistically significant difference in the eradication rates of the 10-day and the 14-day groups (RR 0.96; 95% CI 0.93, 1.00;  $I^2=75$ ) in the PP analysis (**Figure 3**).

### *Adverse Effects*

All the included studies mentioned details regarding the adverse effects, with gastrointestinal symptoms being the most prominent ones. However, treatment duration did not significantly impact the risk of adverse events, as the risk of adverse events was not significantly different between the two groups (RR 0.80; 95% CI 0.63, 1.02;  $I^2=59\%$ ) (**Figure 4**). The studies demonstrated significant heterogeneity.

The adverse effects most commonly reported by studies were epigastric discomfort and pain, nausea, and vomiting. Additionally, the study by Yang et al. reported a significantly lower incidence of dizziness and vomiting in the 10-day group compared to the 14-day group [12].

### *Compliance*

The compliance rate was reported by five studies included in the analysis. The compliance rate in the 10-day group was 94.6%, compared to 93.0% in the 14-day group. There was no significant difference in the compliance rate between the study groups (RR 1.02; 95% CI 1.00, 1.04;  $I^2=0\%$ )

(**Figure 5**). There was no significant heterogeneity observed in the studies assessing for compliance rate.

## **Discussion**

In this meta-analysis, which included data from 7 RCTs, we evaluated the efficacy and safety of two treatment regimens for treatment-naïve *H. Pylori*-infected individuals: a 10-day BQT and a 14-day BQT. The analysis included 2,424 patients and concluded that there was no significant difference in eradication rates between the two groups. Furthermore, the risk of adverse events and compliance rates were comparable between the two treatment durations. These findings suggest that both regimens are equally effective and safe for treating *H. Pylori* infections, providing flexibility in treatment duration without compromising the efficacy or safety. The risk of bias in the studies included in this review was mostly moderate, with one study having a low risk of bias.

Our findings align with previous studies showing no significant difference in eradication rates between 10-day and 14-day BQT regimens for *H. Pylori*. However, the previous meta-analysis assessing the two treatment regimens exhibited a statistically significant difference in the risk of adverse events, with the 10-day group having fewer adverse reactions [19]. This was not concordant with our meta-analysis, as the two groups demonstrated no significant difference in the risk of adverse events. This is further backed by the latest trials by He et al., Lu et al., and Yang et al. that showed comparable risk of adverse events between the two groups [10–12]. This difference can be explained by the observation that meta-analyses involving studies with small sample sizes may provide significant results that are not substantiated by subsequent larger trials [20].

Among the included studies, the trial by He et al. showed significant improvement in eradication rates in the 14-day BQT group over the 10-day BQT group in both the ITT and PP analysis. This study was also the largest trial to date comparing the two therapies. Drug resistances were demonstrated against clarithromycin and antofloxacin, with minimal resistance against amoxicillin. This study also demonstrated that drug resistance significantly reduced the odds of *H. pylori* eradication. The 10-day therapy group had a significantly lower eradication rate than the 14-day therapy group for antibiotic-resistant strains. [10]. Niu et al. demonstrated that the greatest incidence of resistance occurred against clarithromycin, metronidazole, and levofloxacin. Additionally, they demonstrated fewer costs incurred by patients on 10-day therapy compared to 14-day therapy [18]. Recent trials have also shown greater cost-effectiveness of the shorter-duration therapy compared to the longer-duration regimen [11].

Current guidelines advocate for the triple as well as bismuth-containing quadruple regimens. While the World Gastroenterology Organization (WGO) recommends a 7-day BQT, 10-day and 14-day regimens are also widely recognized and used, especially in areas of higher antibiotic resistance [21]. While metronidazole and tetracycline are the most preferred antibiotics, the addition of bismuth to standard triple therapy containing clarithromycin has shown favorable results [22]. There is current evidence to support that the 7-day therapy may not be inferior to 14-day therapy against antibiotic-resistant strains [23]. Further investigation into the treatment of drug-resistant strains is still required.

The previous meta-analysis was significantly limited by the small sample size and low power of the results. Additionally, the fixed effects model of statistical analysis was used despite significant heterogeneity in the included studies concerning the individual regimens, populations, and sample sizes. The fixed effects model tends to give greater weight to studies with larger

sample sizes, thus undermining the effects of small sample size studies [24]. Also, it is not reasonable to assume that the intervention effects across all studies are identical, as the analysis demonstrates differences in the individual study effects [25]. We believe the sample sizes and interventional effects between the studies are adequately different; hence, a random effects model should be used. There was significant antibiotic resistance reported in one of the studies within the region being studied. [17,26]. This can hinder the comparability of results across studies, as other studies did not report similar resistance in their regions. Moreover, the study by Etik Ozer et al. reported two different pairs of 10-day and 14-day BQT, which were pooled together into a single intervention and control groups [16]. Our study assessed the two pairs separately.

Our study includes data from seven RCTs, providing a robust sample size and enhancing the reliability of the results. Moreover, by focusing on treatment-naïve individuals, the study ensures that the results are not influenced by prior treatments and associated antibiotic resistance. Incorporating the latest RCTs, our study provides up-to-date evidence, reflecting the most recent clinical practices and findings in the treatment of *H. Pylori*. Moreover, by including studies from diverse geographic regions with larger sample sizes, our findings are more generalizable and applicable to a wider range of populations.

The non-inferiority of the 10-day BQT group demonstrated by our study also has logistical benefits. It reduces the wastage of drugs required for disease treatment while also reducing out-of-pocket costs for patients who would have to pay more for the longer duration of therapy [27]. This becomes even more important in the context of developing countries, which face medication shortages on a larger scale [28].

Clinicians may prescribe either the 10-day or 14-day BQT regimen, with knowledge of both treatments having comparable efficacy. This flexibility allows personalized treatment plans tailored to individual patient needs and circumstances. With no significant difference in outcomes, healthcare providers can optimize resource use by selecting the most appropriate regimen based on factors such as cost, availability, and patient preference without compromising treatment success. Our findings highlight the need for continued research on long-term outcomes and recurrence rates.

Another cost-effective method with a high eradication rate is sequential therapy, which has only recently been used in the context of quadruple therapy. It offers a high eradication rate with significant cost-effectiveness, which should be investigated further in large sample-size RCTs [29,30].

## **Limitations**

This study has some limitations, mainly the lack of longer follow-up times, which hinders the assessment of re-infection or long-term adverse events. Most of the studies had biases related to the randomization process (mainly the concealment of allocation) or selection bias. All the trials were single-center studies; such studies have limited external validity of the results and may overestimate the effect of the intervention. [31,32]

## **Conclusion**

Our meta-analysis comparing the 10-day and 14-day BQT regimens for treatment-naïve *H. Pylori* infections found no significant difference in eradication rates, compliance, or incidence of adverse events between the two treatment durations. These findings suggest that both regimens



are equally effective and safe for *H. Pylori* eradication, providing flexibility in treatment choices based on patient preferences, logistical constraints, and clinical circumstances.

## References

- [1] Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of *Helicobacter pylori* Infection: Systematic Review and Meta-Analysis. *Gastroenterology* 2017;153:420–9. <https://doi.org/10.1053/j.gastro.2017.04.022>.
- [2] Chen Y-C, Malfertheiner P, Yu H-T, Kuo C-L, Chang Y-Y, Meng F-T, et al. Global Prevalence of *Helicobacter pylori* Infection and Incidence of Gastric Cancer Between 1980 and 2022. *Gastroenterology* 2024;166:605–19. <https://doi.org/10.1053/j.gastro.2023.12.022>.
- [3] Kyoto global consensus report on *Helicobacter pylori* gastritis - PMC n.d. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552923/> (accessed June 4, 2024).
- [4] Suerbaum S, Michetti P. *Helicobacter pylori* Infection. *New England Journal of Medicine* 2002;347:1175–86. <https://doi.org/10.1056/NEJMra020542>.
- [5] Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of *Helicobacter pylori* infection: the Maastricht III Consensus Report. *Gut* 2007;56:772–81. <https://doi.org/10.1136/gut.2006.101634>.
- [6] Shah S, Cappell K, Sedgley R, Pelletier C, Jacob R, Bonafede M, et al. Healthcare costs among patients with newly diagnosed *helicobacter pylori* infection in the United States: a linked claims-EHR study. *Journal of Medical Economics* 2023;26:1227–36. <https://doi.org/10.1080/13696998.2023.2263252>.
- [7] Gené E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating *Helicobacter pylori* infection: a meta-analysis. *Aliment Pharmacol Ther* 2003;17:1137–43. <https://doi.org/10.1046/j.1365-2036.2003.01566.x>.
- [8] ZHENG Q, CHEN WJ, LU H, SUN QJ, XIAO SD. Comparison of the efficacy of triple versus quadruple therapy on the eradication of *Helicobacter pylori* and antibiotic resistance. *Journal of Digestive Diseases* 2010;11:313–8. <https://doi.org/10.1111/j.1751-2980.2010.00457.x>.
- [9] Muñoz N, Sánchez-Delgado J, Baylina M, Puig I, López-Góngora S, Suarez D, et al. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for *Helicobacter pylori*. *Helicobacter* 2018;23:e12488. <https://doi.org/10.1111/hel.12488>.
- [10] He X-J, Wang X-L, Huang X-Y, Li D-Z, Liu G, Wang W, et al. Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for *Helicobacter pylori* eradication: A randomized trial. *Clinics and Research in*

Hepatology and Gastroenterology 2023;47:102052.

<https://doi.org/10.1016/j.clinre.2022.102052>.

- [11] Lu L, Wang Y, Ye J, Han Y, Lou G, Li Y, et al. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for *Helicobacter pylori* infection: A single-center, open-label, noninferiority, randomized controlled trial. *Helicobacter* 2023;28:e12940. <https://doi.org/10.1111/hel.12940>.
- [12] Yang E-H, Chen W-Y, Chiang H-C, Li C-H, Wu I-H, Chen P-J, et al. 10-Day versus 14-day bismuth quadruple therapy for first-line eradication of *Helicobacter pylori* infection: a randomised, open-label, non-inferiority trial. *eClinicalMedicine* 2024;70:102529. <https://doi.org/10.1016/j.eclinm.2024.102529>.
- [13] Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. <https://doi.org/10.1136/bmj.n71>.
- [14] Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019;366:l4898. <https://doi.org/10.1136/bmj.l4898>.
- [15] Chen Y, Liu Q, Hu F, Ma J. Identifying the best regimen for primary eradication of *Helicobacter pylori*: analysis of 240 cases. *MicrobiologyOpen* 2020;9:e1120. <https://doi.org/10.1002/mbo3.1120>.
- [16] Etik DO, Sezer S, Clinic of Gastroenterology, Ankara Yenimahalle Hospital, Ankara, Turkey, Suna N, Department of Gastroenterology, Baskent University School of Medicine, Ankara, Turkey, Oztas E, et al. Can the treatment duration be shortened in bismuth-containing therapies for *Helicobacter pylori* eradication? *Turk J Gastroenterol* 2019;30:667–72. <https://doi.org/10.5152/tjg.2019.18793>.
- [17] Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-Day Bismuth-Containing Quadruple Therapy for *Helicobacter Pylori* Eradication: A Randomized Trial of 10 and 14 Days: Duration of Bismuth Quadruple Therapy for *H. pylori* Infection. *Helicobacter* 2011;16:295–300. <https://doi.org/10.1111/j.1523-5378.2011.00857.x>.
- [18] Niu M, Bai F. Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of *Helicobacter pylori*. *Front Pharmacol* 2022;13. <https://doi.org/10.3389/fphar.2022.771876>.
- [19] Ding Y-M, Li Y-Y, Liu J, Wang J, Wan M, Lin M-J, et al. The cure rate of 10-day bismuth-containing quadruple therapy for *Helicobacter pylori* eradication is equivalent to 14-day: a systematic review and meta-analysis. *Clin Exp Med* 2022;23:1033–43. <https://doi.org/10.1007/s10238-022-00953-7>.
- [20] Sivakumar H, Peyton PJ. Poor agreement in significant findings between meta-analyses and subsequent large randomized trials in perioperative medicine. *British Journal of Anaesthesia* 2016;117:431–41. <https://doi.org/10.1093/bja/aew170>.
- [21] World Gastroenterology Organisation (WGO). World Gastroenterology Organisation (WGO) n.d. <https://www.worldgastroenterology.org> (accessed June 6, 2024).
- [22] McNicholl AG, Bordin DS, Lucendo A, Fadeenko G, Fernandez MC, Voynovan I, et al. Combination of Bismuth and Standard Triple Therapy Eradicates *Helicobacter pylori* Infection in More than 90% of Patients. *Clin Gastroenterol Hepatol* 2020;18:89–98. <https://doi.org/10.1016/j.cgh.2019.03.048>.

- [23] Moon S-G, Lim C-H, Kang H-J, Choi A, Kim S, Oh J-H. Seven Days of Bismuth-Based Quadruple Therapy Is as Effective for the First-Line Treatment of Clarithromycin-Resistant Confirmed *Helicobacter pylori* Infection as 14 Days of Bismuth-Based Quadruple Therapy. *JCM* 2022;11:4440. <https://doi.org/10.3390/jcm11154440>.
- [24] Henmi M, Copas JB. Confidence intervals for random effects meta-analysis and robustness to publication bias. *Statist Med* 2010;29:2969–83. <https://doi.org/10.1002/sim.4029>.
- [25] Chapter 10: Analysing data and undertaking meta-analyses n.d. <https://training.cochrane.org/handbook/current/chapter-10> (accessed June 6, 2024).
- [26] Realdi G, Dore MP, Piana A, Atzei A, Carta M, Cugia L, et al. Pretreatment antibiotic resistance in *Helicobacter pylori* infection: results of three randomized controlled studies. *Helicobacter* 1999;4:106–12. <https://doi.org/10.1046/j.1523-5378.1999.99002.x>.
- [27] Shukar S, Zahoor F, Hayat K, Saeed A, Gillani AH, Omer S, et al. Drug Shortage: Causes, Impact, and Mitigation Strategies. *Front Pharmacol* 2021;12. <https://doi.org/10.3389/fphar.2021.693426>.
- [28] Walker J, Chaar BB, Vera N, Pillai AS, Lim JS, Bero L, et al. Medicine shortages in Fiji: A qualitative exploration of stakeholders' views. *PLoS One* 2017;12:e0178429. <https://doi.org/10.1371/journal.pone.0178429>.
- [29] Vaira D, Zullo A, Hassan C, Fiorini G, Vakil N. Sequential Therapy for *Helicobacter Pylori* Eradication: The Time is Now! *Therapeutic Advances in Gastroenterology* 2009;2:317. <https://doi.org/10.1177/1756283X09343326>.
- [30] Liou J-M, Chen C-C, Fang Y-J, Chen P-Y, Chang C-Y, Chou C-K, et al. 14-day sequential therapy versus 10-day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of *Helicobacter pylori*: a multicentre, non-inferiority, randomized trial. *Journal of Antimicrobial Chemotherapy* 2018;73:2510–8. <https://doi.org/10.1093/jac/dky183>.
- [31] Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. *Crit Care Med* 2009;37:3114–9. <https://doi.org/10.1097/CCM.0b013e3181bc7bd5>.
- [32] Unverzagt S, Prondzinsky R, Peinemann F. Single-center trials tend to provide larger treatment effects than multicenter trials: a systematic review. *Journal of Clinical Epidemiology* 2013;66:1271–80. <https://doi.org/10.1016/j.jclinepi.2013.05.016>.

**Figure Legends:**

**Figure 1:** PRISMA flowchart for selection of studies.

**Figure 2:** Forest plot for eradication (Intention-to-treat analysis).

**Figure 3:** Forest plot for eradication rate (Per-protocol analysis).

**Figure 4:** Forest plot for adverse events.

**Figure 5:** Forest plot for compliance rate.

Study ID	Location	Included study arms	Included Participants	Mean Age $\pm$ SD in years	Male %	Duration of Follow-up
<b>Chen 2020</b>	China	10-day vs 14-day Rabeprazole BQT	120 vs 120	45.89 $\pm$ 12.92 vs 48.11 $\pm$ 12.39	56.7 vs 50.8	4 weeks
<b>Dore 2011</b>	Italy	10-day vs 14-day Bismuth, Tetracycline, Metronidazole, and Esomeprazole	215 vs 202	52 vs 53	37.7 vs 35.6	4-6 weeks
<b>Etik Ozer 2019</b>	Turkey	10-day vs 14-day bismuth-containing quadruple treatment group (10-BQT vs 14-BQT groups)	54 vs 54	40 $\pm$ 11.0 vs 44 $\pm$ 12.5	31.5 vs 35.2	6-12 weeks
		10-day vs 14-day moxifloxacin-bismuth combined treatment groups (10-MBCT vs 14-MBCT groups)	54 vs 54	41 $\pm$ 11.5 vs 43 $\pm$ 11.5	40.7 vs 42.6	
<b>He 2023</b>	China	10-day vs 14-day Antofloxacin containing BQT (ANT10 vs ANT14)	395 vs 387	43.0 $\pm$ 11.8 vs 44.2 $\pm$ 11.1	51.6 vs 55.3	6 weeks
<b>Lu 2023</b>	China	10-day vs 14-day Vonoprazan BQT	78 vs 78	37.1 $\pm$ 19.7 vs 35.9 $\pm$ 11.5	41.0 vs 47.4	6-8 weeks
<b>Niu and Bai 2022</b>	China	10-day vs 14-day Ilaprazole, Amoxicillin, Furazolidone, Bismuth Glycyrrhizinate (10-IAFB vs 14-IAFB)	150 vs 150	44.25 $\pm$ 12.67 vs 44.10 $\pm$ 13.90	45.5 vs 42.1	4-6 weeks
<b>Yang 2024</b>	Taiwan	10-day vs 14-day Bismuth Quadruple Therapy (10-BQT vs 14-BQT)	157 vs 156	55.0 $\pm$ 14.6 vs 55.0 $\pm$ 13.0	52.9 vs 42.9	At least 4 weeks

**Table 1: Study characteristics of the included studies.**

## Previous studies

## Identification of new studies via databases and registers

### Identification

Studies included in previous version of review (n = 4)

Reports of studies included in previous version of review (n = 4)

Records identified from:  
Databases (n = 270)  
Registers (n = 39)

Records removed *before screening*:  
Duplicate records removed (n = 42)

### Screening

Records screened (n = 267)

Records excluded (n = 213)

Reports sought for retrieval (n = 54)

Reports not retrieved (n = 2)

Reports assessed for eligibility (n = 52)

Reports excluded:

- 1) Studies comparing dual/triple therapy with quadruple therapy (n = 25)
- 2) Studies not comparing 10 and 14-day therapies (n = 14)
- 3) Studies other than randomized controlled trials (n = 10)

### Included

New studies included in review (n = 3)  
Reports of new included studies (n = 3)

Total studies included in review (n = 7)  
Reports of total included studies (n = 7)













